vs
ADMA BIOLOGICS, INC.（ADMA）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $-139.5M）。过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -100.0%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
ADMA vs RVMD — 直观对比
营收规模更大
ADMA
是对方的Infinity倍
$0
自由现金流更多
ADMA
多$174.1M
$-139.5M
两年增速更快
ADMA
近两年复合增速
-100.0%
损益表 — Q4 2025 vs Q4 2024
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $0 |
| 净利润 | $49.4M | $-194.6M |
| 毛利率 | 63.8% | — |
| 营业利润率 | 45.1% | — |
| 净利率 | 35.5% | — |
| 营收同比 | 18.4% | — |
| 净利润同比 | -55.9% | -20.4% |
| 每股收益（稀释后） | $0.20 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMARVMD
| Q4 25 | $139.2M | — | ||
| Q3 25 | $134.2M | — | ||
| Q2 25 | $122.0M | — | ||
| Q1 25 | $114.8M | — | ||
| Q4 24 | $117.5M | $0 | ||
| Q3 24 | $119.8M | $0 | ||
| Q2 24 | $107.2M | $0 | ||
| Q1 24 | $81.9M | $0 |
净利润ADMARVMD
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | — | ||
| Q2 25 | $34.2M | — | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $111.9M | $-194.6M | ||
| Q3 24 | $35.9M | $-156.3M | ||
| Q2 24 | $32.1M | $-133.2M | ||
| Q1 24 | $17.8M | $-116.0M |
毛利率ADMARVMD
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
营业利润率ADMARVMD
| Q4 25 | 45.1% | — | ||
| Q3 25 | 38.0% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 30.4% | — | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | — | ||
| Q2 24 | 36.6% | — | ||
| Q1 24 | 26.7% | — |
净利率ADMARVMD
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 23.4% | — | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | — | ||
| Q2 24 | 29.9% | — | ||
| Q1 24 | 21.7% | — |
每股收益（稀释后）ADMARVMD
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.45 | $-1.13 | ||
| Q3 24 | $0.15 | $-0.94 | ||
| Q2 24 | $0.13 | $-0.81 | ||
| Q1 24 | $0.08 | $-0.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $2.3B |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $2.3B |
| 总资产 | $624.2M | $2.6B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMARVMD
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | $2.3B | ||
| Q3 24 | $86.7M | $1.5B | ||
| Q2 24 | $88.2M | $1.6B | ||
| Q1 24 | $45.3M | $1.7B |
总债务ADMARVMD
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMARVMD
| Q4 25 | $477.3M | — | ||
| Q3 25 | $431.2M | — | ||
| Q2 25 | $398.3M | — | ||
| Q1 25 | $373.4M | — | ||
| Q4 24 | $349.0M | $2.3B | ||
| Q3 24 | $231.9M | $1.6B | ||
| Q2 24 | $188.3M | $1.6B | ||
| Q1 24 | $153.7M | $1.7B |
总资产ADMARVMD
| Q4 25 | $624.2M | — | ||
| Q3 25 | $568.7M | — | ||
| Q2 25 | $558.4M | — | ||
| Q1 25 | $510.6M | — | ||
| Q4 24 | $488.7M | $2.6B | ||
| Q3 24 | $390.6M | $1.8B | ||
| Q2 24 | $376.4M | $1.8B | ||
| Q1 24 | $350.9M | $1.9B |
负债/权益比ADMARVMD
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $-139.5M |
| 自由现金流率自由现金流/营收 | 24.8% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $-567.7M |
8季度趋势，按日历期对齐
经营现金流ADMARVMD
| Q4 25 | $35.6M | — | ||
| Q3 25 | $13.3M | — | ||
| Q2 25 | $21.1M | — | ||
| Q1 25 | $-19.7M | — | ||
| Q4 24 | $50.2M | $-138.3M | ||
| Q3 24 | $25.0M | $-130.4M | ||
| Q2 24 | $45.6M | $-128.2M | ||
| Q1 24 | $-2.2M | $-160.6M |
自由现金流ADMARVMD
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | $-139.5M | ||
| Q3 24 | $24.0M | $-133.9M | ||
| Q2 24 | $43.6M | $-130.6M | ||
| Q1 24 | $-4.6M | $-163.7M |
自由现金流率ADMARVMD
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
资本支出强度ADMARVMD
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
现金转化率ADMARVMD
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
